Kano Therapeutics Secures $7.1 Million in Funding to Revolutionize Genetic Medicine with Non-Viral DNA Insertion
Kano Therapeutics, a forward-thinking biotechnology firm emerging from MIT, has announced the successful closure of a $7.1 million funding round, underscoring its potential to reshape the landscape of genetic medicine. This financing includes an oversubscribed $5 million seed round co-led by The Engine Ventures and VSquared Ventures, with additional support from Taihill Venture and Metaplanet….